Synthetic peptides as tools for investigating the pathogenicity of disease: humoral hypercalcemia of malignancy
McKee, R.L.; Caulfield, M.P.
Peptide Research 2(2): 161-166
1989
ISSN/ISBN: 1040-5704 PMID: 2520752 Document Number: 326440
Document emailed within 1 workday
Related Documents
Rosol, T.J.; Nagode, L.A.; Robertson, J.T.; Leeth, B.D.; Steinmeyer, C.L.; Allen, C.M. 1994: Humoral hypercalcemia of malignancy associated with ameloblastoma in a horse Journal of the American Veterinary Medical Association 204(12): 1930-1933Onuma, E.; Sato, K.; Saito, H.; Tsunenari, T.; Ishii, K.; Esaki, K.; Yabuta, N.; Wakahara, Y.; Yamada-Okabe, H.; Ogata, E. 2004: Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy Anticancer Research 24(5a): 2665-2673
Brondz, B.D.; Anafalova, T.V.; Pavlova, L.S.; Pankratova, E.V.; Kozhich, A.G.; Moshnikov, S.A. 1993: Use of a series of synthetic peptides and purified major histocompatibility complex i (H-2K(b)) molecules for inhibiting T-suppressors, specific for the K(b) molecule, and their induction by peptides in vivo Molekuliarnaia Biologiia 27(4): 773-780
Openshaw, S. 1996: Methods for investigating localized clustering of disease. Using a geographical analysis machine to detect the presence of spatial clustering and the location of clusters in synthetic data Iarc Scientific Publications 135: 68-86; Discussion: 155-164
Yamaguchi, K. 1991: Malignancy-associated hypercalcemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(3): 343-349
McCoy, D.J.; Beasley, R. 1986: Hypercalcemia associated with malignancy in a horse Journal of the American Veterinary Medical Association 189(1): 87-89
Mazzaferri, E.L.; O'Dorisio, T.M.; LoBuglio, A.F. 1978: Treatment of hypercalcemia associated with malignancy Seminars in Oncology 5(2): 141-153
Tai, N.; Inoue, D. 2014: Treatment of malignancy associated hypercalcemia Clinical Calcium 24(8): 1223-1228
Esbrit, P. 2001: Hypercalcemia of Malignancy - New Insights into an Old Syndrome Clinical Laboratory 47(1-2): 67-71
Horowitz, E.; Miller, J.L.; Rose, L.I. 1991: Etidronate for hypercalcemia of malignancy and osteoporosis American Family Physician 43(6): 2155-2159
Kaplan, M. 1994: Hypercalcemia of malignancy: a review of advances in pathophysiology Oncology Nursing Forum 21(6): 1039-1046; Quiz: 1047-1048
Monno, S.; Nagata, A.; Homma, T.; Oguchi, H.; Kawa, S.; Kaji, R.; Furuta, S. 1984: Exocrine pancreatic cancer with humoral hypercalcemia American Journal of Gastroenterology 79(2): 128-132
Steward, M.W.; Howard, C.R. 1985: The potential of synthetic peptides for vaccines Medical Laboratory Sciences 42(4): 376-387
Paiva, A.C. 1973: Synthetic angiotensin inhibiting peptides Acta Physiologica Latino Americana 23(6): 530-532
Kazakova, O.V.; Orekhovich, V.N. 1982: Hydrolysis of synthetic peptides by group D cathepsins Biokhimiia 47(9): 1448-1453
Lasarte, J.J.; Sarobe, P.; Golvano, J.; Prieto, I.; Civeira, M.P.; Gullón, A.; Sarin, P.S.; Prieto, J.; Borrás-Cuesta, F. 1994: CD4-modified synthetic peptides containing phenylalanine inhibit HIV-1 infection in vitro Journal of Acquired Immune Deficiency Syndromes 7(2): 129-134
Kulik, L.N.; Ivanov, V.S.; Chikin, L.D.; Berkova, N.P.; Kozhich, A.T.; Gabriélian, A.E.; Ivanova, V.T. 1994: Modeling antigenic determinants of the hepatitis a virus using synthetic peptides Bioorganicheskaia Khimiia 20(7): 709-719
Widmann, C.; Maryanski, J.L.; Romero, P.; Corradin, G. 1991: Differential stability of antigenic MHC class I-restricted synthetic peptides Journal of Immunology 147(11): 3745-3751
Sandhu, D.P.; Cooksey, G.; O'Reilly, K.; Gordon-Smart, J. 1991: Squamous cell carcinoma of the renal pelvis associated with urinary diversion and humoral hypercalcaemic malignancy syndrome Journal of the Royal College of Surgeons of Edinburgh 36(3): 192-194
Motté, P.; Alberici, G.; Ait-Abdellah, M.; Bellet, D. 1987: Monoclonal antibodies distinguish synthetic peptides that differ in one chemical group Journal of Immunology 138(10): 3332-3338